NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$2.25
+0.00% today
Updated 2026-04-29
Market cap
$405.57M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$1 – $4
Volume
1.1M
Neumora Therapeutics, Inc. (NMRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $1.55M | $2.70M | $668000.00 | — | $5.00M |
| Gross profit | — | — | $-1.55M | $-2.70M | $-668000.00 | — | $-5.00M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | — | $87.13M | $212.78M | $104.75M | $142.72M | $200.93M | $176.06M |
| SG&A | — | $8.39M | $24.55M | $31.12M | $45.48M | $62.54M | $60.09M |
| Operating income | — | $-95.52M | $-237.32M | $-135.87M | $-188.19M | $-263.46M | $-241.16M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | — | $-95.41M | $-236.78M | $-135.28M | $-187.53M | $-262.83M | $-233.37M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-252000.00 | $-95.52M | $-237.32M | $-135.87M | $-188.19M | $-263.46M | $-233.58M |
| Interest expense | — | — | — | — | — | — | $3.22M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-99.27M | $-237.31M | $-130.90M | $-235.93M | $-243.79M | $-236.93M |
| Net income growth (YoY) | — | — | -139.1% | +44.8% | -80.2% | -3.3% | +2.8% |
| Profit margin | — | — | — | — | — | — | — |